Nemtabrutinib for blood cancers after prior treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a performance status (ECOG) of 0–2 and be able to take part in daily activities
- Have at least 3 months of expected life, as judged by your study doctor
- Be able to swallow and keep down an oral pill (and plan to take it by mouth)
- Have enough organ function based on blood tests and other checks
- Have had appropriate prior treatment for your exact cancer type (CLL/SLL, Richter transformation, mantle cell lymphoma, marginal zone lymphoma, follicular lymphoma, or Waldenström’s macroglobulinemia)
- Have measurable or active disease on scans or tests (rules vary by cancer type)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
This trial tests a new medicine (nemtabrutinib) in people with severe kidney disease to see how the body handles it. The study helps doctors decide safe doses for people with kidney problems.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.